Cochlear Limited (CHEOY) Stock: Price, Forecast & Analyst Target
Cochlear Limited (CHEOY) — price $45.45 (+4.29%), as of the Oct 5, 2026 trading session; market cap $5.94B.
Educational signal · not a buy or sell recommendation · How to read this
Cochlear Limited · CHEOY · Healthcare · Medical - Devices
Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $45.45 | |
| Change on the day | +4.29% | |
| 52-week range | $31.82 – $98.49 | |
| Market capitalisation | $5.94B | |
| Price / earnings (trailing) | 57.66 | |
| Shares traded on the day | 369 | |
| Beta (volatility vs the S&P 500) | 0.26 | |
| Dividends per share (last 12 months) | $1.23 | |
| Dividend yield (last 12 months) | 2.81% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Other perspectives
Council score for Cochlear (CHEOY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CHEOY film — every key number, told as a short cinematic story
~2 min · open the film
What is Cochlear (CHEOY), and what does it report?
Short answer · as of
Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world. Healthcare / Medical Devices Headquarters: 1 University Avenue, Sydney, NSW, 2109, AU. It employs 5,400 people and is led by Diggory William Howitt. In Q4 FY2026 it reported revenue of $819M and net income of -$10M. The market values it at $5.94B.
What do the latest results show for Cochlear (CHEOY)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $819M.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $770.35M Feb 11, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Feb 11, 2026 | $770.35M | Not available | $0.8110 | Not available |
| Aug 13, 2025 | $774.57M | Not available | $0.9180 | Not available |
| Feb 13, 2025 | $725.27M | Not available | $0.9660 | Not available |
| Aug 15, 2024 | $758.17M | Not available | $0.8400 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $819M | -$10M | -$0.08 (diluted) |
| Q2 FY2026 | $805M | $110M | $0.84 (diluted) |
| Q4 FY2025 | $827M | $128M | $0.98 (diluted) |
| Q2 FY2025 | $817M | $143M | $1.09 (diluted) |
What are the financial strengths and risks for Cochlear (CHEOY)?
Short answer
The distress and quality screens read Altman Z 9.21 · Piotroski F 6. Trailing ratios: ROE 18.1% · ROA 11.3% · current ratio 2.46.
What should you watch next at Cochlear (CHEOY)?
Short answer · as of
Current published price targets run low $117.00 · high $117.00 · consensus $117.00 · median $117.00 against a quoted price of $45.45 (as of Oct 5, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $117.00 – $117.00
- Consensus target
- $117.00
- Median target
- $117.00
Consensus record · Captured .
Measured against a quoted price of $45.45 (as of Oct 5, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.0% Prior to period end Jun 30, 2026
- Reporting holders
- 3 Period end Jun 30, 2026
- Previous quarter · holders
- 4 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Rhumbline Advisers | 7,004 |
| Gamma Investing LLC | 1,932 |
| Salomon & Ludwin, LLC | 184 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Cochlear (CHEOY)?
Common Questions About CHEOY (Healthcare)
These answers are editorial: 1 of these 8 answers is drawn from the CHEOY research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CHEOY a good stock to buy?
Stock Expert AI does not rate CHEOY buy, sell or hold. Cochlear Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CHEOY stock price today?
The last price recorded on this page for Cochlear Limited (CHEOY) is $45.45, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CHEOY price target?
The analyst consensus price target for Cochlear Limited (CHEOY) is $117.00 (range $117.00 to $117.00, median $117.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does Cochlear Limited do?
Cochlear Limited specializes in providing implantable hearing solutions, primarily cochlear implants and bone conduction systems. These devices are designed to restore or improve hearing for individuals with varying degrees of hearing loss, from severe to profound.
What are the key factors to evaluate for CHEOY?
Evaluate CHEOY on fundamentals, analyst consensus, and risk factors. P/E: 57.66x. Analysts target $117.00 (+157%). This focus on innovation will help Cochlear maintain its competitive edge and drive long-term growth. Not financial advice.
How frequently does CHEOY data refresh on this page?
CHEOY's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CHEOY's recent stock price performance?
Cochlear Limited (CHEOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global leader in implantable hearing solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHEOY overvalued or undervalued right now?
Cochlear Limited (CHEOY) trades at 57.66x earnings. Analysts target $117.00 (+157%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (40 figures)
The 40 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 34 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $45.45 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:54:54.111Z. | |
px.change | Change on the day | +4.29% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.94B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T19:58:23.000Z. Captured from FMP at 2026-10-05T21:54:53.091Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$1.87 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 57.66 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 369 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.26 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Devices | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 1 University Avenue, Sydney, NSW, 2109, AU | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 5,400 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Diggory William Howitt | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q4 FY2026 | $819M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2026 | -$10M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-02-11.revenue_actual | Revenue · reported — report date 2026-02-11 | $770.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_actual | EPS · reported — report date 2026-02-11 | $0.8110 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-13.revenue_actual | Revenue · reported — report date 2025-08-13 | $774.57M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-13.eps_actual | EPS · reported — report date 2025-08-13 | $0.9180 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-13.revenue_actual | Revenue · reported — report date 2025-02-13 | $725.27M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-13.eps_actual | EPS · reported — report date 2025-02-13 | $0.9660 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-08-15.revenue_actual | Revenue · reported — report date 2024-08-15 | $758.17M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-08-15.eps_actual | EPS · reported — report date 2024-08-15 | $0.8400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $117.00 · high $117.00 · consensus $117.00 · median $117.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $117.00 – $117.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $117.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $117.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 3 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 4 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Rhumbline Advisers — shares in provider snapshot | 7,004 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Gamma Investing LLC — shares in provider snapshot | 1,932 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Salomon & Ludwin, LLC — shares in provider snapshot | 184 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $31.82 – $98.49 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 9.21 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 18.1% · ROA 11.3% · current ratio 2.46 | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.23 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.81% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-02-11. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-02-11.revenue_actual,earn.history.depth.2026-02-11.eps_actual,earn.history.depth.2025-08-13.revenue_actual,earn.history.depth.2025-08-13.eps_actual,earn.history.depth.2025-02-13.revenue_actual,earn.history.depth.2025-02-13.eps_actual,earn.history.depth.2024-08-15.revenue_actual,earn.history.depth.2024-08-15.eps_actual.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.